Giant prolactinomas: the therapeutic approach
AB Moraes, C Marques dos Santos Silva… - Clinical …, 2013 - Wiley Online Library
Background Giant prolactinomas are an unusual subset of macroprolactinomas and are
more commonly found in men. The goal of this review is to propose a giant prolactinoma …
more commonly found in men. The goal of this review is to propose a giant prolactinoma …
[HTML][HTML] Cellular and molecular specificity of pituitary gland physiology
C Perez-Castro, U Renner, MR Haedo… - Physiological …, 2012 - journals.physiology.org
The anterior pituitary gland has the ability to respond to complex signals derived from central
and peripheral systems. Perception of these signals and their integration are mediated by …
and peripheral systems. Perception of these signals and their integration are mediated by …
Reciprocal regulation of GAS5 lncRNA levels and mTOR inhibitor action in prostate cancer cells
K Yacqub‐Usman, MR Pickard, GT Williams - The prostate, 2015 - Wiley Online Library
BACKGROUND New therapies are required for castrate‐resistant prostate cancer (CRPC),
and growth‐arrest specific 5 (GAS5) lncRNA, which riborepresses androgen receptor action …
and growth‐arrest specific 5 (GAS5) lncRNA, which riborepresses androgen receptor action …
Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer
High-grade non-muscle invasive bladder cancer (HG-NMIBC) is a clinically unpredictable
disease with greater risks of recurrence and progression relative to their low-intermediate …
disease with greater risks of recurrence and progression relative to their low-intermediate …
Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer
Introduction Inappropriate DNA methylation is frequently associated with human tumour
development, and in specific cases, is associated with clinical outcomes. Previous reports of …
development, and in specific cases, is associated with clinical outcomes. Previous reports of …
Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas
Persistent androgen receptor (AR) signaling in castration resistant prostate cancer (CRPC)
underpins the urgent need for therapeutic strategies that better target this pathway …
underpins the urgent need for therapeutic strategies that better target this pathway …
Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs
Context: Dopamine agonists (DA) are the first choice treatment of prolactinomas. However, a
subset of patients is resistant to DA, due to undefined dopamine D2 receptor (D2R) …
subset of patients is resistant to DA, due to undefined dopamine D2 receptor (D2R) …
[HTML][HTML] Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline
SJ Lin, ZG Leng, YH Guo, L Cai, Y Cai, N Li… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract Cabergoline (CAB), the first-line drug for treatment of prolactinomas, is effective in
suppressing prolactin hypersecretion, reducing tumor size, and restoring gonadal function …
suppressing prolactin hypersecretion, reducing tumor size, and restoring gonadal function …
Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels
S Shimazu, A Shimatsu, S Yamada… - European journal of …, 2012 - academic.oup.com
Objective Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in
responsive prolactinoma. However, several cases have shown resistance to dopamine …
responsive prolactinoma. However, several cases have shown resistance to dopamine …
The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment
YT Liu, F Liu, L Cao, L Xue, WT Gu, YZ Zheng… - Acta …, 2020 - Springer
Pituitary adenoma (PA) is one of the most common intracranial tumors, and approximately
40% of all PAs are prolactinomas. Dopamine agonists (DAs), such as cabergoline (CAB) …
40% of all PAs are prolactinomas. Dopamine agonists (DAs), such as cabergoline (CAB) …